-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
At present, 1 out of every 352 people in the world suffers from Crohn's disease (CD).
At present, 1 out of every 352 people in the world suffers from Crohn's disease (CD).
The treatment goal of CD is mucosal healing (MH), but the evaluation of MH requires ileocolonoscopy, which is an invasive and expensive examination item that is difficult to implement clinically
diagnosis
Researchers conducted a retrospective cohort study at a tertiary IBD center in the United Kingdom and included patients with all CD events diagnosed from 2005 to 2017 in this study
Finally, a total of 375 patients were included in this study, with a median follow-up time of 5.
Figure: The effect of changes in fecal calprotectin levels on disease recurrence
Through this retrospective study, the authors confirmed that the normalization of FC in patients with CD within 12 months after diagnosis is associated with a reduced risk of CD progression
Original source:
Nikolas Plevris.
Related Products
